Park Hyejin, Urs Aarti N, Zimmerman Joseph, Liu Chuan, Wang Qiu, Urs Nikhil M
Department of Chemistry, Duke University, Durham, North Carolina 27708, United States.
Department of Pharmacology and Therapeutics, University of Florida, Gainesville Florida 32610, United States.
ACS Med Chem Lett. 2020 Jan 6;11(3):385-392. doi: 10.1021/acsmedchemlett.9b00575. eCollection 2020 Mar 12.
Loss of dopamine neurons is central to the manifestation of Parkinson's disease motor symptoms. The dopamine precursor L-DOPA, the most commonly used therapeutic agent for Parkinson's disease, can restore normal movement yet cause side-effects such as dyskinesias upon prolonged administration. Dopamine D1 and D2 receptors activate G-protein- and arrestin-dependent signaling pathways that regulate various dopamine-dependent functions including locomotion. Studies have shown that shifting the balance of dopamine receptor signaling toward the arrestin pathway can be beneficial for inducing normal movement, while reducing dyskinesias. However, simultaneous activation of both D1 and D2Rs is required for robust locomotor activity. Thus, it is desirable to develop ligands targeting both D1 and D2Rs and their functional selectivity. Here, we report structure-functional-selectivity relationship (SFSR) studies of novel apomorphine analogs to identify structural motifs responsible for biased activity at both D1 and D2Rs.
多巴胺神经元的丧失是帕金森病运动症状表现的核心。多巴胺前体左旋多巴是帕金森病最常用的治疗药物,它可以恢复正常运动,但长期使用会引起诸如运动障碍等副作用。多巴胺D1和D2受体激活G蛋白和抑制蛋白依赖性信号通路,这些通路调节包括运动在内的各种多巴胺依赖性功能。研究表明,将多巴胺受体信号平衡转向抑制蛋白途径有利于诱导正常运动,同时减少运动障碍。然而,强大的运动活性需要D1和D2Rs同时激活。因此,开发同时靶向D1和D2Rs及其功能选择性的配体是很有必要的。在这里,我们报告了新型阿扑吗啡类似物的结构-功能-选择性关系(SFSR)研究,以确定在D1和D2Rs上具有偏向活性的结构基序。